计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N413987-5mg |
5mg |
现货 ![]() |
| |
| N413987-25mg |
25mg |
现货 ![]() |
| |
| N413987-100mg |
100mg |
现货 ![]() |
| |
| N413987-250mg |
250mg |
现货 ![]() |
|
| 英文别名 | 1H-Isoindole-4-carboxamide, 2-(1-(4,4-difluorocyclohexyl)-4-piperidinyl)-6-fluoro-2,3-dihydro-3-oxo- | AT32155 | EX-A1271 | 2-[1-(4,4-Difluorocyclohexyl)-piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide | 2-[1-(4,4-difluorocyclohexyl) |
|---|---|
| 规格或纯度 | ≥97% |
| 英文名称 | NMS-P118 |
| 生化机理 | NMS-P118 是一种强效、口服、高选择性 PARP-1 抑制剂,具有出色的 ADME 和药代动力学特征,对 PARP-1 的选择性是 PARP-2 的 150 倍(Kd 分别为 0.009 μM 和 1.39 μM)。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
Information NMS-P118 is a potent, orally available, and highly selectivePARP-1inhibitor endowed with excellent ADME and pharmacokinetic profiles, showing 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively). Targets PARP1 (Cell-free assay) 0.009 μM(Kd) In vitro NMS-P118 is a potent (KD = 0.009 μM) PARP-1 inhibitor, showing 150-fold selectivity over PARP-2 (KD = 1.39 μM). The compound shows high solubility and permeability. In vivo NMS-P118 is proved to be metabolically stable, it modestly inhibits two cytochrome P450 family members (CYP-2B6 IC50, 8.15 μM; CYP-2D6 IC50, 9.51 μM) out of eight isoforms tested. NMS-P118 has low in vivo clearance, and complete oral bioavailability. The pharmacokinetic profile of NMS-P118 in rat dosed iv at 10 mg/kg and orally at 10 and 100 mg/kg, mirrors that observed in the mouse, with oral bioavailability >65%, and linearity of exposure with dose. Its treatment dramatically decreases intratumoral PAR levels at 1, 2, and 6 h after administration and partial recovery of PAR levels is observed at 24 h. NMS-P118 shows excellent ADME and pharmacokinetic profiles, high oral availability in the mouse and rat, and high efficacy both as a single agent and in combination with Temozolomide in BRCA1-mutated MDA-MB-436 and BRCA2 deficient Capan-1 human tumor xenograft models, respectively. Cell Research(from reference) Cell lines:HeLa cells Incubation Time:30 mins |
| 纯度 | ≥97% |
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488201439 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-1H-isoindole-4-carboxamide |
| INCHI | 1S/C20H24F3N3O2/c21-13-9-12-11-26(19(28)17(12)16(10-13)18(24)27)15-3-7-25(8-4-15)14-1-5-20(22,23)6-2-14/h9-10,14-15H,1-8,11H2,(H2,24,27) |
| InChi Key | ARYVAQSYRLZVQD-UHFFFAOYSA-N |
| Smiles | C1CC(CCC1N2CCC(CC2)N3CC4=C(C3=O)C(=CC(=C4)F)C(=O)N)(F)F |
| Isomeric SMILES | C1CC(CCC1N2CCC(CC2)N3CC4=C(C3=O)C(=CC(=C4)F)C(=O)N)(F)F |
| 分子量 | 395.42 |
| Reaxy-Rn | 21181864 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=21181864&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 79 mg/mL warmed with 50ºC Water: bath (199.78 mM); Ethanol: 10 mg/mL warmed with 50ºC Water: bath (25.28 mM); Water: Insoluble; |
|---|---|
| 分子量 | 395.400 g/mol |
| XLogP3 | 2.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 395.182 Da |
| 单同位素质量Monoisotopic Mass | 395.182 Da |
| 拓扑极表面积Topological Polar Surface Area | 66.600 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 614.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 | |
| 分析证书 | N413987 |